Branded Legacy, Inc. (OTC: BLEG) has announced that its subsidiary BioLegacy Evaluative Group has acquired a 22,000-square-foot commercial property in Vancouver, Canada. The biotechnology company, focused on addiction treatment and harm reduction, will utilize the new facility as a laboratory and manufacturing hub for developing devices and products designed to counteract hazardous substances and reduce associated harms.
The facility features GMP-compliant operations with ISO Class 7 and 8 clean rooms, enabling the production of medical-grade products. Located in the center of Vancouver's drug crisis, the strategic positioning allows BioLegacy to collaborate directly with affected populations while advancing technologies supported by partnerships with McMaster University and Stanford University's Dr. Eran Bendavid.
Branded Legacy's patented intranasal naloxone delivery device, which enhances accessibility and dosing precision for opioid overdose treatment, represents one of the key technologies that will benefit from the expanded manufacturing capabilities. The platform also enables nasal delivery of vaccines and other medications, creating opportunities in global markets for rapid pandemic response and improved access in underserved regions.
The acquisition aligns with the company's focus on developing innovative solutions to combat addiction by preventing overdoses and supporting recovery. For more information about the company's initiatives, visit https://BrandedLegacy.com. The expansion into Vancouver's market represents a significant step in addressing the ongoing public health challenges associated with substance abuse and addiction treatment accessibility.
